News

Ankyra Therapeutics, a biotechnology company developing cancer therapies based on localized cytokines that prime a systemic adaptive immune response, and Lonza announced a collaboration to manufacture Ankyra’s cytokine-based immunotherapy for cancer patients. Lonza will provide cell line optimization and...

Lonza announced significant investments to expand its mammalian drug substance manufacturing facilities in Visp (CH) and Portsmouth (US). The expansion in Visp (CH) will see the development of a new large-scale mammalian drug substance manufacturing facility to expand capacity with...

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, and Promethera Biosciences, the leader in advanced therapy development for severe liver diseases, announced that...

Sanofi has entered into a three-year research collaboration with Stanford University School of Medicine. Together, the two organizations and their scientists will work to advance the understanding of immunology and inflammation through open scientific exchange. Additionally, Sanofi will provide...

Novavax, Inc., a biotechnology company developing next-generation vaccines for serious infectious diseases, announced that it has finalized an advance purchase agreement (APA) with Gavi, the Vaccine Alliance (Gavi) for supply of its recombinant protein-based COVID-19 vaccine candidate to the...

This development is part of CytoDyn’s agreement to collaborate with AEIH to carry out the trials in up to 45 clinical sites in the country. These Phase III trials are anticipated to deliver the data required by the Brazilian regulatory...

Eiger BioPharmaceuticals has said that its investigational agent, Peginterferon Lambda, will be added to the Phase III TOGETHER platform study of Covid-19 outpatients in Brazil. A type III interferon (IFN), Lambda induces immune responses required for developing host protection during...